Assessment of tumor growth inhibition metrics to predict overall survival
Clin Pharmacol Ther
.
2014 Aug;96(2):135-7.
doi: 10.1038/clpt.2014.112.
Authors
L Claret
1
,
R Bruno
1
Affiliation
1
Pharsight Consulting Services, Pharsight, A Certara Company, Marseille, France.
PMID:
25056390
DOI:
10.1038/clpt.2014.112
No abstract available
Publication types
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology*
Female
Humans
Male